Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Mark Cooper, MD

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

SGLT2i reduces patient-reported HF symptom burden in HFrEF

News - June 30, 2020

HFA Discoveries These analyses of patient-reported outcomes in EMPERIAL trials suggest a trend towards reductions in HF symptom burden with empagliflozin compared to placebo in HFrEF patients.

Beneficial effect of SGLT2i in HFrEF independent of use of diuretic therapy

News - June 23, 2020

HFA Discoveries This analysis of the DAPA-HF trial showed that the benefits of dapagliflozin persisted irrespective of use of diuretics or diuretic dose.

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD
The mechanisms and beneficial cardiorenal effects of SGLT2 inhibitors in diabetic patients are dicussed in this video by Maria Rosa Costanzo, MD

Dr. Constanzo explains the function of SGLT2 in the early proximale tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.

New SGLT2 inhibitor non-inferior to placebo for CV outcomes

News - June 17, 2020

ADA 2020 The VERTIS-CV trial demonstrated CV safety with ertugliflozin, but no decrease in MACE was observed with ertugliflozin compared to placebo in T2DM patients with CVD.

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD
Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

Icosapent ethyl reduces both first and total CV events in diabetes patients

News - June 16, 2020

ADA 2020 A prespecified analysis from REDUCE-IT demonstrated that first and total (first plus recurrent) CV events were reduced with icosapent ethyl compared to placebo in patients with diabetes.

ATP citrate lyase inhibitor lowers LDL-c across glycemic status subgroups

News - June 16, 2020

ADA 2020 The ATP citrate lyase inhibitor bempedoic acid lowered LDL-c compared to placebo in high-risk CV patients across all glycemic status subgroups, shown by a pooled analysis from four phase 3 trials.

SGLT2i reduces risk of new-onset T2DM

News - June 15, 2020

ADA 2020 The SGLT2 inhibitor dapagliflozin reduced risk of new-onset T2DM in HFrEF patients, demonstrated by a prespecified analysis of the DAPA-HF trial.

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD
The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

GLP-1RA therapy results in smaller decline of eGFR

News - June 9, 2020
An analysis of pooled data from CVOT trials that evaluated semaglutide showed that semaglutide slowed down decline of eGFR compared to placebo.

ERA-EDTA 2020 An analysis of pooled data from CVOT trials that evaluated semaglutide showed that semaglutide slowed down decline of eGFR compared to placebo.

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Mark Cooper, MD
In this presention by Mark Cooper, an overview is given of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2i, and their effect on kidney outcomes in CDK and DKD patients.

Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CDK and DKD patients. With question